|
WO2019096137A1
|
|
Hybridoma comprising immune checkpoint inhibitor, preparation method for same, and applications thereof
|
|
WO2019096136A1
|
|
Anti-pd-1 antibody, preparation method therefor and use thereof
|
|
CN111132687A
|
|
Therapeutic peptide compositions for excitotoxicity-related injuries
|
|
CN110799522A
|
|
Peptides for treating, ameliorating or preventing cerebral hemorrhage and uses thereof
|
|
WO2019006692A1
|
|
Compound for treating, ameliorating, or preventing disease related to nervous system and use thereof
|
|
EP3650460A1
|
|
Polypeptide pharmaceutically acceptable salt et use thereof
|
|
CN108617638A
|
|
Tissue and/or cell cryopreservation protection liquid and its preparation and application
|
|
CN108530517A
|
|
Stimulate polypeptide, the fusion protein and preparation method thereof of activated immune cell
|
|
CN108218996A
|
|
Recombinant protein and its method for preparing purified
|
|
CN110049994A
|
|
A kind of conjugate and its application
|
|
CN107964039A
|
|
One kind restructuring GP96-ScFv albumen and its preparation method and application
|
|
CN107913395A
|
|
Nerve excitability damages purposes of the related polypeptide in prevention, alleviation or treatment pain
|
|
CN107574148A
|
|
A kind of NK (NK cells) culture medium and preparation method thereof
|
|
KR20180135492A
|
|
Peptides for the treatment of excitatory neurotoxicity-related damage
|
|
KR20180135493A
|
|
Treatment of excitatory neurotoxicity-related impairment
|
|
CN107312069A
|
|
The treatment peptide of excititoxic associated injury
|
|
CN107312071A
|
|
The treatment method of excititoxic associated injury
|
